The objective of this study was to determine whether pregnancy is associated with an acceleration of human immunodeficiency virus (HIV) disease progression in women who have a pregnancy while HIV infected. A retrospective review of all women aged 15-35 years who attended an HIV outpatient program from January 1989 through August 1995, was undertaken. The 192 women who had a term pregnancy after testing positive for HIV were compared with 164 women who were not pregnant during the same period. The main outcome measures were death, the occurrence of a first acquired immunodeficiency syndrome (AIDS)-defining condition, or a condition indicative of symptomatic HIV. Disease progression was assessed using the Kaplan-Meier method and multivariate proportional hazards models. Compared with nonpregnant women, women with a term pregnancy were significantly more likely to be African-American (88% vs. 78%, p < 0.05), younger than 22 years of age (51 % vs. 11 %, p < 0.001), and to have entered the clinic with a higher median CD4 count (519 vs. 433 cells/pj, p < 0.001). After adjusting for entry CD4 count and other factors, pregnancy was not associated with progression to any of the study outcomes. Thus, in women attending a publicly funded clinic, pregnancy does not appear to accelerate the progression of HIV disease. Am J Epidemiol 1998;147:434-40. acquired immunodeficiency syndrome; blacks; disease progression; HIV; pregnancy; women Women now constitute 20 percent of cases of acquired immunodeficiency syndrome (AIDS) in the United States (1). The majority of AIDS cases in women have occurred among those aged 25-39 years, and heterosexual contact is the most rapidly increasing transmission category for women (2). Since most women infected with the human immunodeficiency virus (HTV) are in their child-bearing years, it is inevitable that many will become pregnant while HIV infected. The rates of pregnancy in HTV-infected women are similar to those in uninfected women (3). With the availability of zidovudine to reduce the risk of perinatal transmission (4), and the recent advances in new anti-retroviral drugs and protease inhibitors that have the potential to make HTV a chronic, medi-
Women now constitute 20 percent of cases of acquired immunodeficiency syndrome (AIDS) in the United States (1) . The majority of AIDS cases in women have occurred among those aged 25-39 years, and heterosexual contact is the most rapidly increasing transmission category for women (2) . Since most women infected with the human immunodeficiency virus (HTV) are in their child-bearing years, it is inevitable that many will become pregnant while HIV infected. The rates of pregnancy in HTV-infected women are similar to those in uninfected women (3) . With the availability of zidovudine to reduce the risk of perinatal transmission (4) , and the recent advances in new anti-retroviral drugs and protease inhibitors that have the potential to make HTV a chronic, medi-cally manageable condition, more HTV-infected women are likely to become pregnant.
A number of clinical reports have suggested an increase in morbidity and mortality among HTVinfected women who become pregnant (5) (6) (7) (8) (9) (10) . Given the lack of comparison groups, small sample sizes, and possible bias introduced by the selection of study subjects, no firm conclusions regarding the effect of pregnancy on HTV disease progression can be made from these studies. Two epidemiologic studies have addressed this question and have found little if any increase in risk of progression associated with pregnancy (11, 12) . Despite the results of these two studies, reports continue to surface of a more accelerated progression of disease in HTV-infected women after pregnancy (13) (14) (15) (16) . Studies of pregnancy and HTV disease progression have not been conducted in North American women.
To clarify these issues, we undertook a study to determine whether pregnancy leads to a faster disease progression in women attending an HIV outpatient program in New Orleans, Louisiana.
MATERIALS AND METHODS Study population
This study was conducted in women (n = 402) attending the HTV Outpatient Program of the Medical Center of Louisiana in New Orleans from January 1988, through August 1995, and who were 35 years of age or younger at entry into the clinic. Women were identified through a clinic database, and information was abstracted from the database and from medical charts. Many of the women were referred to the clinic after testing positive for HTV at a prenatal visit, and entered the program pregnant or postpartum.
Data collection
The clinic database provided information on demographic characteristics, intravenous and nonintravenous drug use, obstetric history, prophylactic therapy for Pneumocystis carinii pneumonia, anti-retroviral therapy, hormonal contraceptive use, CD4 cell count, and clinical diagnoses. During the study period, antiretroviral therapy was almost exclusively zidovudine. In addition to visits to the HTV Outpatient Program, the database provided information abstracted from medical charts from other facilities, including the obstetric clinic, early intervention clinics, and inpatient services. Additional information on pregnancy, including pregnancy outcome, was abstracted from clinic charts for the purposes of this study.
Any pregnancy that occurred after the women tested positive for HTV was recorded. Only women with a pregnancy that resulted in a live birth were considered as pregnant for the purposes of this study. Women who had an elective abortion or a miscarriage, and who did not have a pregnancy that resulted in a birth, were excluded from the analysis (n = 46). Disease progression in these women was compared with progression in women who did not become pregnant after testing positive for HIV.
Length of follow-up was considered to be the number of months from the initial clinic visit to the ending date of the last 6-month interval in which the woman made a clinic visit, or August 31, 1996, whichever came first. There were three study outcomes considered: symptomatic HTV, AIDS, and death. The date of the first occurrence of oral thrush, herpes zoster, or oral hairy leukoplakia was considered to be the date of onset of symptomatic HTV. Constitutional symptoms, such as chronic diarrhea, night sweats, weight loss, and fatigue, were not used as indicators of disease progression due to the subjectivity involved in diagnosis, the lack of evidence that they are strong predictors of disease progression, and the possibility that these factors could be severely confounded by pregnancy and other events during the postnatal period. AIDS was defined as the occurrence of any one of the conditions in the 1987 Centers for Disease Control and Prevention surveillance definition. Deaths were ascertained through the clinic and the AIDS surveillance program at the Louisiana State Office of Public Health.
Statistical analysis
The initial analyses concerned the 192 women who had a term pregnancy either prior to entry, at entry, or during follow-up by the HTV Outpatient Program, and the 164 women who were not pregnant during the same period. The association of potential confounding factors with each of the study outcomes and with pregnancy status was assessed using univariate analysis. Chi square and Fisher's exact test were used to assess associations of categorical variables, and the Mann-Whitney test was used for the continuous variables. Multivariate proportional hazards models were use in a forward stepwise fashion to assess the association of pregnancy and each study outcome after adjusting for potential confounding factors. CD4 count at clinic entry (<200 cells//xl, 200-500 cells//xl, >500 cetis/fxl) was included in the model as two dummy variables.
The subset analyses concerned the 45 women who became pregnant (and whose pregnancy resulted in a live birth) after entry into the HTV Outpatient Program. Disease progression in these women was compared with disease progression in a sample of women who were never pregnant during the study period and who were matched on closest CD4 counts at clinic entry. Only nonpregnant women with at least 12 months of follow-up were eligible for inclusion in the comparison group, since all of the pregnant women had at least 12 months of follow-up. The follow-up of both groups of women was extended to June 30, 1996. As in the initial analyses of the entire cohort, sociodemographic and clinical characteristics were examined in relation to the study outcomes in univariate analysis. Kaplan-Meier curves for progression to symptomatic HTV, AIDS, and death were used to assess progression in the pregnant and nonpregnant women. Crude relative risks and relative risks adjusted for race and age were obtained using proportional hazards models.
RESULTS
The women included in the study were primarily African-American (83 percent), single (71 percent), and became infected with HTV through heterosexual sex (47 percent), intravenous drug use (25 percent), or had no identified risk factor for HTV transmission (23 percent). Twenty-nine percent were 22 years of age or younger at entry into the study. Over half of the women received medical care through Medicare or Medicaid funding (55 percent), and an additional 26 percent received free care at the clinic. Almost all of the women (93 percent) had experienced at least one pregnancy at entry into the clinic and 78 percent had given birth at least once. Sixty-nine women (17 percent) had a history of an elective abortion and 70 (17 percent) had a history of at least one miscarriage.
A total of 192 women had a term pregnancy after testing positive for HTV. Of these, 136 women (71 percent) had given birth by the time they entered the HTV outpatient program, 85 (44 percent) were pregnant at entry, and 45 (23 percent) had a subsequent pregnancy that resulted in a birth after entering the program. Several women were pregnant more than once while HTV infected. The breakdown of CD4 cell count at the time of first pregnancy is as follows: 23 (12 percent) had <200 cells//ul, 92 (48 percent) had 200-500 cells//u,l, and 76 (40 percent) had >500 cells/ A comparison of baseline characteristics at clinic entry between the pregnant and nonpregnant women revealed some significant differences (table 1) . Women with a term pregnancy were significantly more likely to be African-American (p < 0.05) and younger than 22 years of age (p < 0.001). The pregnant women were also more likely to have been infected with HTV through heterosexual sex and to have no identified risk factor for transmission, and less likely to have been infected through intravenous drug use (p < 0.05). With respect to obstetric history, the pregnant women were less likely to have a history of miscarriage (p < 0.05) but were not significantly different in terms of having had a prior abortion or having one, or more than one, live births. A comparison of clinical characteristics showed that the pregnant women had a significantly higher median CD4 cell count at entry (519 versus 333 cells/p,!,/? < 0.001) and were less likely to enter the clinic with an AFDSdefining opportunistic infection (1.6 percent versus 18.9 percent, p < 0.001).
In the subset of women who had a CD4 count <200 cells/^il during follow-up, the use of P. carinii pneumonia prophylactic therapy was similar in the women with a term pregnancy and in the nonpregnant women (93 and 97 percent, respectively) (p < 0.50). In a comparison of anti-retroviral drug use in women who had a CD4 count <500 cells//xl during follow-up, the nonpregnant women were slightly more likely to have used anti-retroviral drugs than the pregnant women (88 percent versus 80 percent, p < 0.06). Anti-retroviral drug use was comparable, however, in the pregnant and nonpregnant women who had a CD4 count <200 cells//xl during follow-up (91 percent vs 93 percent, p > 0.50).
Women who had a term pregnancy were followed for a median of 32 months (range 1-92), whereas the nonpregnant women were followed for a median of 20 months (range 1-96) (p < 0.001). In table 2, the multivariate proportional hazards model for each of the study endpoints are presented. After adjusting for entry CD4 count and age, term pregnancy was not significantly associated with progression to symptomatic HTV (relative risk (RR) = 0.82, 95 percent confidence interval (CI) 0.53-1.20), AIDS (RR = 0.90, 95 percent CI 0.49-1.66), or death (RR = 0.55, 95 percent CI 0.28-1.11). Other factors not found to be associated with progression after adjusting for entry CD4 cell count, and, therefore, not included in the model, were race, intravenous drug use, P. carinii pneumonia prophylactic therapy, anti-retroviral therapy, and hormonal contraceptive use (results not shown).
Subset analysis
Of the 74 women who became pregnant after clinic entry, 45 had a term pregnancy and are the focus of this analysis. Disease progression in these women was compared with progression in 45 nonpregnant women with similar CD4 cell counts. The distribution of CD4 count at the time of pregnancy for the women was as follows: 10 women had <200 cells//xl (22 percent), 24 women had 200-500 cells//xl (53 percent), and 11 women had >500 cells//xl (24 percent). Similarities and differences in demographic characteristics between the two groups reflect those of the entire cohort of pregnant and nonpregnant women presented previously. The median CD4 count in the pregnant women was 560 cells//i,l as compared with 589 cells/^tl in the nonpregnant women (p > 0.80). Two women in the pregnant group and four in the nonpregnant group had an AIDS-defining condition at entry {p > 0.40). The use of prophylactic and anti-retroviral drugs during follow-up was not significantly different with respect to pregnancy status.
Kaplan-Meier product moment methods were used to compare progression with each of the study outcomes in the pregnant women and the nonpregnant women. There was no significant difference in survival between the two groups (p > 0.30). Progression to symptomatic HTV and to AIDS was also similar (p > 0.30 for both comparisons) (figure 1). Multivariate proportional hazards models were used to adjust for differences in demographic characteristics. After adjusting for age and race, the relative risk for symptomatic HTV for the pregnant women was 1.63 (95 percent CI 0.66-4.03), for AIDS the relative risk was 1.25 (95 percent CI 0.38-4.12), and for death it was 0.98 (95 percent CI 0.27-3.59) (table 3). 
DISCUSSION
This study examined the relation between having a term pregnancy and the progression of HTV disease in a cohort of women attending an HTV outpatient clinic. After adjusting for CD4 cell count at entry and other factors, pregnancy was not associated with any of the study endpoints. In the analysis of the women who became pregnant after clinic entry, a larger proportion of pregnant versus nonpregnant women had symptomatic HTV, AIDS, or had died by the end of follow-up, though the difference was not statistically significant.
A similar study of pregnancy and disease progression in Haitian women also showed a slight but statistically nonsignificant increase in progression associated with pregnancy (11) . The authors noted an increase in the relative hazard for progression to AIDS and a slight increase in progression to symptomatic HTV and death, although the differences in progression were not significant. In a similar study in France (12), pregnant and nonpregnant women were matched on CD4 count category at entry and then followed over time. The relative hazards for AIDS, a CD4 count below 200 cells/pil, and death all approached 1.
None of the demographic characteristics investigated were found to be independently associated with disease progression in the present study. Although older age has been identified as a risk factor for HTV disease progression in other studies (17) (18) (19) , the relatively narrow age distribution in this cohort (15-35 years) may account for the lack of association. As with the demographic factors, use of anti-retroviral therapy was not significantly associated with disease progression after adjusting for entry CD4 cell count.
The strengths of this study include the large number of women enrolled in the HTV Outpatient Program during the study period and the large proportion of these women who were also pregnant. In addition, the sample of women was relatively homogeneous with respect to socioeconomic status and access to medical care, factors that are often difficult to measure and to control for. Further, this is the only published study of pregnancy and HTV disease progression done in North American women.
With respect to limitations, the results of this study are likely to be generalizable only to women who are similar to those attending the HIV Outpatient Program and not to all HTV-infected women of reproductive age. In addition to the sociodemographic profile of the study sample, the exclusion of women older than 35 years to enhance internal validity also limits the generalizability of these results. The cohort also consisted primarily of mildly and moderately immunosuppressed women. These results cannot, therefore, be extrapolated to women with AIDS or severe immunosuppression.
Selection bias may have been introduced by including only women who had a term pregnancy. Several studies (20) (21) (22) have shown that immunosuppression is most evident late in pregnancy; consequently, women with a term pregnancy would be at highest risk for disease progression. If pregnancy outcome were associated with the health status of the mother, selection of women with a term pregnancy would result in an underestimate of risk associated with pregnancy. An increased rate of miscarriage has been found in at least one study of women with symptomatic HIV infection (23) . Elective abortion has also been associated with poorer health status at the time of pregnancy in at least one study of HIV-infected women (24) , although this was not found in a study of women attending the HTV Outpatient Program (25) . To examine the possibility of selection bias, the degree of immunosuppression was compared in the women who had a term pregnancy and those who miscarried or electively aborted the pregnancy. No significant dif- ferences were found. In fact, the CD4 count at the time of pregnancy was slightly lower in the women who carried the pregnancy to term than in either the women who electively terminated or the women who miscarried the pregnancy. Becoming pregnant may also be associated with survival in several ways. It is likely that women who are healthier are more Likely to be sexually active and to become pregnant. It is also possible that women who have more advanced disease may be more likely to have menstrual abnormalities and, perhaps, lower fertility. In a multicenter study of HTV-infected women in the United States, the authors found a slight increase in amenorrhea in HTV-infected women as compared with HTV-negative women (26) . A study of HTV-infected women in Uganda showed a significant reduction in rates of pregnancy (27) . With respect to health status at the time of the pregnancy, Chu et al. (28) found that HTV-infected women with an AIDS opportunistic illness were significantly less likely to become pregnant compared with HTV-infected women without AIDS. Finally, in a study of pregnancy in women attending the HIV Outpatient Program in New Orleans, pregnancy rates were much higher in women with CD4 counts greater than 200 cells//xl (25) .
It is possible that the slight, nonsignificant increase in risk of progression associated with pregnancy in the analysis of the women who became pregnant after clinic entry may be due to ascertainment bias. Women who were pregnant may have been more closely followed by the clinic, increasing the chance of diagnosis of infections indicative of advancing disease. In addition, since the children of these women are also seen by the HIV Outpatient Program, the additional visits for the child may have provided additional opportunities for maternal infections to be detected. The relative risk for progression associated with pregnancy was only elevated for symptomatic HTV and AIDS, conditions that require diagnosis. There was no increase in risk of mortality. A further consideration concerns the use of CD4 count at clinic entry to adjust for differences in disease stage at entry between the two groups. Of the 192 women who had a complete pregnancy, approximately one-third had pregnancies that occurred prior to entry into the clinic, and the first CD4 count was not available until after the pregnancy was completed. Therefore, the use of the CD4 count at entry to adjust for disease stage may have removed any effect on progression associated with pregnancy. If pregnancy causes an initial decrease in CD4 cell count but does not lead to an increased rate of decline of CD4 cell count during the course of infection, then the initial effect would not be detectable. Another approximately one-third of the pregnant women were pregnant at entry into the program, and thus had the first CD4 count done while they were pregnant. As in the case of the women entering the clinic postpartum, the validity of using the entry CD4 count to adjust for disease stage must be considered. If pregnancy is associated with changes in lymphocyte levels, then a CD4 count during pregnancy may not be an accurate measure of immune function at entry. The analysis restricted to women who became pregnant after clinic entry was performed because the CD4 count performed at entry in these women was considered to be a more valid indicator of the disease stage prior to the pregnancy.
To a greater or lesser extent, the aforementioned biases limit the conclusions that can be drawn from this study. However, these results do suggest that having a term pregnancy while HIV infected does not have a significant impact on the progression of HIV disease. Although there is no apparent acceleration of disease progression, it is still unclear whether women who have AIDS at the time of their pregnancy are at increased risk of death. In addition, this study did not address the question of whether HIV-infected women have more frequent or more severe episodes of disease than women who do not become pregnant.
